Medicine Experts

Stephen A. Hill

Chubby Chicks Cupcakes


Dr. Hill has been a member of the Board of Directors since 2007, and served as its Chairman from 2007 until 2015. Dr. Hill has served Faraday Pharmaceuticals' Chief Executive Officer since August of 2015. He previously served as CEO and President of Targacept, Inc., a biopharmaceutical company developing a diverse pipeline of NNR Therapeutics. In August 2015, Targacept merged with Catalyst Biosciences Inc. Prior to joining Targacept, Dr. Hill served as President of Solvay Pharmaceuticals, Inc. from 2008 to 2010. Solvay was acquired by Abbott Labs in 2010. From 1999 to 2008, Dr. Hill served as President and CEO of ArQule where he successfully implemented the company’s transition from a chemistry services platform to an integrated research and development organization. From 1997 to 1999, Dr. Hill served as Global Head of Clinical Development for Roche Products. He currently serves on the board of directors for publicly held companies Catalyst Biosciences and Lipocine, Inc., in addition to Cellectar. Dr. Hill earned his bachelor and medical degrees from The University of Oxford and practiced medicine in the field of orthopedic surgery prior to his career in the biopharmaceutical industry. Dr. Hill’s extensive experience in a broad range of senior management positions with companies in the life sciences sector make him a highly qualified member of our Board of Directors.

Research Interest

pharmaceutical science 

Global Experts from Israel

Global Experts in Subject